PBAC's latest decision on Bimatoprost: Recommended (2020). Considered for For the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.
PBAC outcome
Recommended
Unrestricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Patients requiring treatment for elevated intraocular pressure or open angle glaucoma, suitable for first-line therapy, monotherapy, or adjunctive therapy to topical beta-blockers.
Therapy area
Ophthalmology
Line of therapy
First-line
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
latanoprost (lowest priced alternative agent)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. All pricing and financial data are redacted (marked with quotation marks in the document).